Algeria vs Russia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Algeria
95.0%
in 2025
Russia
95.0%
in 2025
Algeria rank
38th
Russia rank
38th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Algeria
- Russia
How they compare
Algeria currently reports 95.0% against 95.0% in Russia, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Russia ahead.
Algeria ranks 38th and Russia ranks 38th of 194 countries.
Across the 3 decades both report, Algeria averaged higher in 1 and Russia in 1.
Head to head by decade
| Decade | Algeria | Russia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 32.8% | 27.1% | 5.7% | Algeria |
| 2020s | 84.8% | 91.7% | 6.8% | Russia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Algeria or Russia?
- Algeria, at 95.0% against 95.0% in Russia as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Algeria and Russia?
- 0.0%, with Algeria ahead.
- How many years of comparable data are there for Algeria and Russia?
- 18 years are reported by both, from 2008 to 2025.
- How do Algeria and Russia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Algeria ranks 38th and Russia ranks 38th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.